The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Baynas     3-[(3R)-3-[(4- fluorophenyl)sulfonylamino]...

Synonyms: Ramatroban, PubChem9956, Bay-u-3405, SureCN29030, Baynas (TN), ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Baynas

 

High impact information on Baynas

 

Chemical compound and disease context of Baynas

  • CONCLUSIONS: Our experience suggests that the pathogenesis of eosinophilic otitis media is related to the pharmaceutical effects of ramatroban, i.e., inhibition of the thromboxane A(2) receptor (TP) and the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) [6].
 

Biological context of Baynas

 

Anatomical context of Baynas

 

Associations of Baynas with other chemical compounds

 

Gene context of Baynas

  • Animals were then treated with or without TP receptor antagonist (S18886, 5 or 10 mg/kg per day; ramatroban, 10 mg/kg per day) or aspirin (30 mg/kg per day) in drinking water for 21 days [14].
  • The thromboxane A2-receptor antagonistic properties of Bay U 3405 [(3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbaz o-lepropanoic acid] have been evaluated in various pharmacologic models [4].
  • From these results, we conclude that Bay U 3405 is an orally active, selective, and competitive thromboxane A2-receptor antagonist that may be beneficial in the treatment of cardiovascular or cerebrovascular diseases [4].
  • The results suggest that ramatroban may not be susceptible to drug-drug interaction involving MRP2/Mrp2 in biliary excretion and absorption [7].
  • The aim of this study was to evaluate whether, after balloon angioplasty of atherosclerotic arteries, ramatroban would reduce MCP-1 expression, macrophage accumulation, and neointimal formation [15].
 

Analytical, diagnostic and therapeutic context of Baynas

References

  1. Thromboxane antagonism in experimental canine carotid artery thrombosis. Rote, W.E., Mu, D.X., Lucchesi, B.R. Stroke (1993) [Pubmed]
  2. Effect of Bay U 3405, a new thromboxane antagonist, on collagen-induced thromboembolism in rabbits. Seuter, F., Perzborn, E., Fiedler, V.B. Stroke (1990) [Pubmed]
  3. Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease. Fiedler, V.B., Seuter, F., Perzborn, E. Stroke (1990) [Pubmed]
  4. Characterization of Bay U 3405, a novel thromboxane A2/endoperoxide receptor antagonist. Perzborn, E., Fiedler, V.B., Seuter, F., Stasch, J.P., Weber, H., Sander, E., Böshagen, H., Rosentreter, U. Stroke (1990) [Pubmed]
  5. On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2. Mathiesen, J.M., Christopoulos, A., Ulven, T., Royer, J.F., Campillo, M., Heinemann, A., Pardo, L., Kostenis, E. Mol. Pharmacol. (2006) [Pubmed]
  6. Successful treatment of eosinophilic otitis media using ramatroban: Report of two cases. Wada, T., Uemaetomari, I., Murashita, H., Tobita, T., Tsuji, S., Tabuchi, K., Okubo, H., Hara, A. Auris, nasus, larynx. (2006) [Pubmed]
  7. Pharmacokinetic analysis of ramatroban using a recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference in Sprague-Dawley and Eisai hyperbilirubinemic rats. Moriwaki, T., Yasui, H., Yamamoto, A. Pharm. Res. (2004) [Pubmed]
  8. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mathiesen, J.M., Ulven, T., Martini, L., Gerlach, L.O., Heinemann, A., Kostenis, E. Mol. Pharmacol. (2005) [Pubmed]
  9. Characterization and localization of thromboxane A2 receptor in human and guinea-pig nasal mucosa using radiolabelled (+)-S-145. Arimura, A., Miwa, M., Hasegawa, H., Kishino, J., Notoya, M., Yasui, K., Komori, M., Iwata, S. Br. J. Pharmacol. (1998) [Pubmed]
  10. Effects of thromboxane A2 receptor antagonist (Bay u 3405) on nasal symptoms after antigen challenge in sensitized guinea pigs. Narita, S., Asakura, K., Kataura, A. Int. Arch. Allergy Immunol. (1996) [Pubmed]
  11. Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction. Magnussen, H., Boerger, S., Templin, K., Baunack, A.R. J. Allergy Clin. Immunol. (1992) [Pubmed]
  12. Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: potentiation of antiplatelet effects of aspirin. Escolar, G., Albors, M., Garrido, M., Bioque, G., Díaz Ricart, M., Carretero, M., Ordinas, A. Eur. J. Clin. Invest. (1998) [Pubmed]
  13. Effect of thromboxane A2-receptor antagonist on bradykinin-induced bronchoconstriction in asthma. Rajakulasingam, K., Johnston, S.L., Ducey, J., Ritter, W., Howarth, P.H., Holgate, S.T. J. Appl. Physiol. (1996) [Pubmed]
  14. Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization. Michel, F., Silvestre, J.S., Waeckel, L., Corda, S., Verbeuren, T., Vilaine, J.P., Clergue, M., Duriez, M., Levy, B.I. Arterioscler. Thromb. Vasc. Biol. (2006) [Pubmed]
  15. Ramatroban, a thromboxane A2 receptor antagonist, prevents macrophage accumulation and neointimal formation after balloon arterial injury in cholesterol-fed rabbits. Ishizuka, T., Matsumura, K., Matsui, T., Takase, B., Kurita, A. J. Cardiovasc. Pharmacol. (2003) [Pubmed]
  16. The effect of BAY u 3405, a thromboxane receptor antagonist, on prostaglandin D2-induced nasal blockage. Johnston, S.L., Smith, S., Harrison, J., Ritter, W., Howarth, P.H. J. Allergy Clin. Immunol. (1993) [Pubmed]
  17. Improved coronary thrombolysis by tissue-type plasminogen activator in the presence of BAY U 3405. Rounding, H.P., Fiedler, V.B. Eur. J. Pharmacol. (1991) [Pubmed]
  18. Involvement of thromboxane A2 in bronchial hyperresponsiveness of asthma. Kanazawa Asthma Research Group. Fujimura, M., Nakatsumi, Y., Nishi, K., Kasahara, K., Matsuda, T. Pulmonary pharmacology. (1995) [Pubmed]
  19. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs. Boberg, M., Ahr, H.J., Beckermann, B., Bühner, K., Siefert, H.M., Steinke, W., Wünsche, C., Hirayama, M. Arzneimittel-Forschung. (1997) [Pubmed]
 
WikiGenes - Universities